Research & Education

Cell Free DNA Diagnostics in Lung Cancer Management

Tuesday, April 12, 2016 at 9 p.m. Eastern Daylight Time - Recording Available

 

 Eric Collisson  

Eric Collisson, MD
Associate Professor of Medicine
Hematology/Oncology
University of California- San Francisco

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

Laurie Gaspar, MD, PhD- Advisory Board/Honoraria: Astrazeneca.

Name of Planner(s): 

Pia Hirsch, USA - Nothing to Disclose

Carlos Ferreira - Nothing to Disclose

Name of Activity: 

Cell Free DNA Diagnostics in Lung Cancer Management

Date of Activity:

04/12/2016

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, planners and faculty et al. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Chair:Ramaswamy Govindan, MD, USA - Speaker Advisory Board with the following: BI, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, ARAID Pharmaceuticals, Astellas;

Honoraruim with the following: Baxalta, Roche

 

Speaker: Eric Collisson, MD, USA- Nothing to Disclose

Type of Activity: 

 Direct Provided

Internet Live Course

1 Hour to Complete

Are there Commercial Supporters for this activity?

   No

If yes, please list:N/A

IASLC continues the Lung Cancer Series in 2016 with this LIVE WEBINAR featuring Dr. Eric Collisson.

This lecture will focus on cell free DNA in lung cancer. Topics covered will include the origin and biology of cell free DNA in this disease. Analytic and clinical validity studies, as well as evidence of clinical utility in medical decision making, will also be discussed.

After attending this session, participants will:

  • Explore the origin and biology of cell free DNA in lung cancer.
  • Analyze the state-of the-art of Cell Free DNA Diagnostics in the management of patients with lung cancer.
  • Implement the clinical utility cell free DNA analysis in medical decision making.

Following the presentation, there will be ample time for discussion and a question/answer session.

Attendees will be able to submit questions and comments to Dr. Collisson via Internet chat.

IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

DOWNLOAD RECORDING

CME INFORMATION:

Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES

All individuals able to influence or control content of any CME certified activity that will be presented were required to complete a Financial Relationships/Conflicts of Interest Disclosure Form prior to the Internet Live Course.

“A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount, and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.”

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest were identified, reviewed and resolved from all individuals involved in the development or able to influence and control the content of this CME activity. IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from future IASLC CME activity presentations. All commercial relationships and conflicts of interest identified were thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and/or an independent reviewer. COI was evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The above Financial Disclosures are from the speakers, moderators, reviewers, and planning committee members (et al.) their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients that are relevant to this presentation(s) or that have provided commercial support for this continuing medical education activity.

CREDIT STATEMENT:

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE:

This lecture will focus on cell free DNA in lung cancer. Topics covered will include the origin and biology of cell free DNA in this disease. Analytic and clinical validity studies, as well as evidence of clinical utility in medical decision making, will also be discussed.

TARGET AUDIENCE:

This CME live webinar was designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physician assistants.

LEARNING OBJECTIVES:

After attending this session, participants will:

  • Explore the origin and biology of cell free DNA in lung cancer.
  • Analyze the state-of the-art of Cell Free DNA Diagnostics in the management of patients with lung cancer.
  • Implement the clinical utility cell free DNA analysis in medical decision making.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The content has been reviewed for conformity with ACCME Essentials, Policies, and Standards for Commercial Support.

TO RECEIVE CME CREDIT:

Upon completion of the electronic evaluation link the CME Certificate will be ready for you to print or save for your records. This information is used not only to evaluate the present activity, but also to plan for future programs.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program.  CME credit is only given for the Internet Live Course.

Use the Time Zone Converter